Geisinger taps EarlySign for new range of AI solutions to identify patients at risk of high-burden diseases
Current Location:
> This Story

Forward Printable StoryPrint Comment




Artificial Intelligence Homepage

Clinithink and Healthix partner to combine artificial intelligence and massive health data

Lunit receives Korea MFDS approval for its AI solution for breast cancer

Automating artificial intelligence for medical decision-making

Mayo Clinic study shows AI could enable accurate screening for atrial fibrillation

Exo Imaging emerges from stealth mode with $35M Series B financing round to advance development of the Exo ultrasound platform

The Lancet - Deep learning AI may identify atrial fibrillation from a normal rhythm ECG

EonDirect develops deep learning applications for abdominal aortic aneurysm patient tracking

VA, DeepMind develop machine learning system to predict life-threatening disease before it appears

AI showcase expands and relocates at RSNA 2019

VIDA announces strategic investment from UnityPoint Health Ventures

Geisinger taps EarlySign for new range of AI solutions to identify patients at risk of high-burden diseases

Press releases may be edited for formatting or style
DANVILLE, PA and TEL AVIV, Israel – July 10, 2019 – Medial EarlySign (, a leader in machine learning-based solutions to aid in early detection and prevention of high-burden diseases, today announced it is partnering with Geisinger and its Steele Institute for Health Innovation to develop and deploy a suite of machine learning-based solutions to identify individuals at risk of a range of chronic and high-burden diseases.

Partnering with Geisinger's Steele Institute for Health Innovation, EarlySign's LGI-Flag™ solution will be deployed to help healthcare practitioners identify patients who are at risk for significant lower GI disorders. LGI-Flag is an advanced software solution that analyzes medical data –including changes in routine blood tests – to flag individuals who will benefit from further evaluation. Reflecting the Steele Institute's efforts to transform healthcare delivery by implementing solutions that improve health, patient experience, care delivery and affordability, the partnership will also explore additional opportunities to benefit patients and their care providers.

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

"Leveraging Geisinger's performance as a national leader in healthcare and its culture of innovation with EarlySign's expertise in machine learning and data analytics will enable us to identify, evaluate and intervene with high-risk patients earlier," said Karen Murphy, PhD, Executive Vice President and Chief Innovation Officer at Geisinger. "This collaboration will help us potentially save lives and improve the care we provide patients by deepening our experience with AI and identifying new ways to integrate it into daily clinical care."

LGI-Flag has been used in healthcare systems around the world since 2015 to identify patients at risk for lower GI disorders associated with chronic occult bleeding. The technology will form the basis for Geisinger and EarlySign to address similar opportunities with other acute and chronic diseases. The partnership will benefit from Geisinger's innovation infrastructure, unique data assets and world-class care teams.

"EarlySign's technology and the LGI-Flag solution will potentially assist our teams to more quickly identify significant lower GI disorders and intervene earlier than we historically have been able to," said Keith A. Boell, D.O., Associate Chief Quality Officer at Geisinger. "We look forward to advancing our use of this technology while leveraging our experience to help more patients benefit from these life-changing medical advances."
  Pages: 1 - 2 >>

Artificial Intelligence Homepage

You Must Be Logged In To Post A Comment